Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Liabilities and Shareholders Equity (2021 - 2026)

Nuvectis Pharma has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $25.4 million for Q1 2026.

  • Quarterly results put Liabilities and Shareholders Equity at $25.4 million for Q1 2026, down 15.76% from a year ago — trailing twelve months through Mar 2026 was $119.7 million (up 41.89% YoY), and the annual figure for FY2025 was $31.7 million, up 70.41%.
  • Liabilities and Shareholders Equity reached $25.4 million in Q1 2026 per NVCT's latest filing, down from $31.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $35.6 million in Q3 2025 and bottomed at $14.2 million in Q2 2022.
  • Median Liabilities and Shareholders Equity over the past 5 years was $20.4 million (2022), compared with a mean of $22.6 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 206.52% in 2022 before it fell 26.63% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $20.4 million in 2022, then fell by 5.98% to $19.2 million in 2023, then decreased by 3.01% to $18.6 million in 2024, then surged by 70.41% to $31.7 million in 2025, then dropped by 19.9% to $25.4 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for NVCT at $25.4 million in Q1 2026, $31.7 million in Q4 2025, and $35.6 million in Q3 2025.